Recorded During the Keystone Symposia Conference on:

Framing the Response to Emerging Virus Infections (S2), Oct 14-18, 2018 | HKU, Hong Kong

This Keystone Symposia Virtual Access was made possible by a grant from the Croucher Foundation and The University of Hong Kong.

The limited protection of current commercial vaccines necessitates the investigation of novel vaccine strategies for unpredictable outbreaks. To investigate the feasibility of using vaccines derived from Group 1 influenza A virus to induce broadly cross-reactive immune responses against multiple influenza subtypes, we tested a panel of sequential 4-dose immunization regimens in mice. Mice were treated with inactivated (seasonal H1N1, pandemic H1N1 and H5N1) and vaccinia virus-based H5N1 live-attenuated vaccines in different combinations.

Mice were then challenged by viruses of either Group 1 (H1N1) or Group 2 (H3N2, H7N7) influenza virus. All studied sequential 4-dose vaccinations could induce some degrees of heterosubtypic protection in mice. Amongst all these regimens, the combined use of inactivated and live-attenuated vaccines could achieve the best heterologous protection. These results highlight the synergistic effect of combining different vaccine platforms to enhance heterosubtypic protection against influenza viruses.

Recorded During the Keystone Symposia Conference on:

Framing the Response to Emerging Virus Infections (S2), Oct 14-18, 2018 | HKU, Hong Kong

This Keystone Symposia Virtual Access was made possible by a grant from the Croucher Foundation and The University of Hong Kong.